Merus Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Merus kazanç ve gelirin sırasıyla yıllık 18.2% ve 54.4% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 23.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -78.8% olacağı tahmin edilmektedir.

Anahtar bilgiler

18.2%

Kazanç büyüme oranı

23.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	27.6%
Gelir büyüme oranı	54.4%
Gelecekteki özkaynak getirisi	-78.8%
Analist kapsamı	Good
Son güncelleme	17 Dec 2024

Gelecekteki son büyüme güncellemeleri

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Recent updates

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Nov 05

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Sep 20

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Aug 14

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Jun 01

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

May 24

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

May 12

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

Dec 18

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Sep 19

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Jun 20

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

May 24

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Feb 08

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Aug 08

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Aug 02

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Jun 30

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

May 14

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Apr 25

New Forecasts: Here's What Analysts Think The Future Holds For Merus N.V. (NASDAQ:MRUS)

Mar 03

We're Not Worried About Merus' (NASDAQ:MRUS) Cash Burn

Nov 25

News Flash: Analysts Just Made A Sizeable Upgrade To Their Merus N.V. (NASDAQ:MRUS) Forecasts

Aug 08

Calculating The Intrinsic Value Of Merus N.V. (NASDAQ:MRUS)

Jul 28

We're Not Very Worried About Merus' (NASDAQ:MRUS) Cash Burn Rate

Jul 02

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:MRUS - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	77	-280	-272	-211	14
12/31/2025	54	-271	-257	-204	16
12/31/2024	36	-248	-219	-191	16
9/30/2024	36	-245	-157	-156	N/A
6/30/2024	35	-168	-104	-103	N/A
3/31/2024	38	-150	-150	-150	N/A
12/31/2023	44	-155	-146	-142	N/A
9/30/2023	46	-177	-142	-136	N/A
6/30/2023	41	-178	-159	-150	N/A
3/31/2023	43	-152	-151	-140	N/A
12/31/2022	42	-131	-158	-150	N/A
9/30/2022	46	-64	-157	-151	N/A
6/30/2022	53	-54	-137	-133	N/A
3/31/2022	52	-76	-126	-125	N/A
12/31/2021	49	-67	-60	-60	N/A
9/30/2021	43	-80	-53	-52	N/A
6/30/2021	38	-89	-42	-41	N/A
3/31/2021	32	-79	-37	-35	N/A
12/31/2020	30	-86	-81	-80	N/A
9/30/2020	29	-83	-76	-75	N/A
6/30/2020	28	-69	-80	-78	N/A
3/31/2020	29	-65	-77	-75	N/A
12/31/2019	31	-55	-66	-63	N/A
9/30/2019	37	-32	-61	-56	N/A
6/30/2019	35	-34	-63	-58	N/A
3/31/2019	36	-26	-50	-45	N/A
12/31/2018	38	-28	-50	-46	N/A
9/30/2018	34	-41	-48	-46	N/A
6/30/2018	33	-45	N/A	-43	N/A
3/31/2018	34	-66	N/A	-54	N/A
12/31/2017	26	-78	N/A	-45	N/A
9/30/2017	18	-100	N/A	-44	N/A
6/30/2017	12	-87	N/A	-33	N/A
3/31/2017	6	-66	N/A	-27	N/A
12/31/2016	3	-50	N/A	-27	N/A
9/30/2016	4	-25	N/A	-27	N/A
6/30/2016	3	-26	N/A	-30	N/A
3/31/2016	3	-27	N/A	-29	N/A
12/31/2015	2	-25	N/A	-25	N/A
9/30/2015	2	-25	N/A	-23	N/A
6/30/2015	2	-23	N/A	-19	N/A
3/31/2015	1	-20	N/A	-17	N/A
12/31/2014	2	-21	N/A	-18	N/A
12/31/2013	1	-14	N/A	-10	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: MRUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: MRUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: MRUS önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: MRUS şirketinin gelirinin (yıllık 54.4% ) US pazarından (yıllık 9.1% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: MRUS şirketinin gelirinin (yıllık 54.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: MRUS 3 yıl içinde kârsız olması bekleniyor.

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 16:26
Gün Sonu Hisse Fiyatı	2024/12/23 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Merus N.V. 22 Bu analistlerden 16, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Etzer Darout	BMO Capital Markets Equity Research
Evan Seigerman	BMO Capital Markets Equity Research
Tazeen Ahmad	BofA Global Research

Merus Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 21% to US$73.36

Consensus revenue estimates increase by 26%

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Price target increased by 7.6% to US$59.18

Price target increased by 16% to US$51.60

Consensus EPS estimates upgraded to US$2.60 loss

Recent updates

Merus N.V. Announces That the United States Food and Drug Administration Approves Bizengri (Zizengri) for Treatment Indicated for Adults with Pancreatic Adenocarcinoma or Non Small Cell Lung Cancer

Merus: Petosemtamab Set Up For December 2024 Data Presentation

Merus N.V. Announces First Patient Dosed in Liger-Hn1, A Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L R/M HNSCC

We're Hopeful That Merus (NASDAQ:MRUS) Will Use Its Cash Wisely

Merus N.V.'s Innovative Cancer Therapies: Balancing Its IP Potential With Financial Risks

Merus N.V. Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC

Merus N.V. Announces Chief Medical Officer Changes

Merus N.V. Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab At the 2024 ASCO® Annual Meeting

Analysts Just Made A Major Revision To Their Merus N.V. (NASDAQ:MRUS) Revenue Forecasts

Merus N.V. has completed a Follow-on Equity Offering in the amount of $400.15 million.

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Price target increased by 21% to US$73.36

Merus Stock: Priced High After An ASCO Surprise Surge (Maintain Buy)

Consensus revenue estimates increase by 26%

Merus N.V. Announces Petosemtamab Grants Breakthrough Therapy Designation by the U.S. FDA

Earnings Beat: Merus N.V. (NASDAQ:MRUS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Merus (NASDAQ:MRUS) Is In A Good Position To Deliver On Growth Plans

First quarter 2024 earnings released: US$0.59 loss per share (vs US$0.86 loss in 1Q 2023)

Merus N.V. Appoints Jason Haddock as Non-Executive Director

Merus N.V., Annual General Meeting, May 07, 2024

Price target increased by 7.6% to US$59.18

Merus N.V. announced that it has received $25.000035 million in funding from Gilead Sciences, Inc.

Full year 2023 earnings: EPS and revenues miss analyst expectations

Merus: Positive Zenocutuzumab Data In 2024 Could Provide BLA Advancement

Price target increased by 16% to US$51.60

Merus N.V. has filed a Follow-on Equity Offering in the amount of $300 million.

Merus N.V.'s (NASDAQ:MRUS) Shares Climb 30% But Its Business Is Yet to Catch Up

Merus Stock: Rally Seems Overdone

Are Investors Undervaluing Merus N.V. (NASDAQ:MRUS) By 45%?

Risks To Shareholder Returns Are Elevated At These Prices For Merus N.V. (NASDAQ:MRUS)

EVP, Company Secretary notifies of intention to sell stock

Consensus EPS estimates upgraded to US$2.60 loss

Consensus estimates of losses per share improve by 12%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Merus N.V. Announces Interim Data Continues to Demonstrate Robust and Durable Responses in NRG1+ Cancer

New major risk - Revenue and earnings growth

We Think Merus (NASDAQ:MRUS) Needs To Drive Business Growth Carefully

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

U.S. Food and Drug Administration Grants Second Breakthrough Therapy Designation for zenocutuzumab (Zeno) of Merus N.V

Merus N.V.'s (NASDAQ:MRUS) Business Is Yet to Catch Up With Its Share Price

Merus Appoints Greg Perry as Chief Financial Officer

Is Merus (NASDAQ:MRUS) In A Good Position To Invest In Growth?

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to US$3.63 loss

Independent Non Executive Director exercised options to buy US$1.5m worth of stock.

Price target increased by 8.6% to US$40.67

Price target increased by 8.5% to US$39.67

Chief Business Officer exercised options to buy US$1.9m worth of stock.

Full year 2022 earnings released: US$2.92 loss per share (vs US$1.73 loss in FY 2021)

Now 21% undervalued

Merus N.V. (NASDAQ:MRUS) Shares Could Be 26% Below Their Intrinsic Value Estimate

Merus N.V. Announces Executive Changes

Price target decreased to US$37.11

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$38.44

Merus N.V. Presents First in Human Data on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus GAAP EPS of -$0.13 beats by $0.49, revenue of $12.68M beats by $2.23M

Merus N.V. initiated with Buy at Stifel based on three bispecific antibodies

Merus: Precision Oncology Pioneer Continues To Execute In The Clinic

Merus N.V. Presents Clinical Data on Zenocutuzumab in NRG1-Fusion Cancer at the 2022 American Society of Clinical Oncology Annual Meeting

Consensus revenue estimates increase by 15%

Need To Know: Analysts Are Much More Bullish On Merus N.V. (NASDAQ:MRUS)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Merus N.V., Annual General Meeting, May 31, 2022

Merus (NASDAQ:MRUS) Is In A Strong Position To Grow Its Business

Executive VP exercised options and sold US$947k worth of stock